The board of directors of CSPC Pharmaceutical Group Limited announced that the antibody-drug conjugate SYS6023 developed by the Group has obtained clinical trial approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China. SYS6023 is a monoclonal antibody-drug conjugate which can bind to specific receptors on the tumor surface and achieve tumor cell killing by entering the cells through endocytosis and releasing toxins. The indications for this clinical trial approval are advanced solid tumors.

Preclinical studies have demonstrated that the Product has good anti-tumor effects on a variety of cancers, which provides promising clinical development values. A number of patent applications of the Product have been submitted.